Literature DB >> 28890642

Reslizumab (Cinqair): An Interleukin-5 Antagonist for Severe Asthma of the Eosinophilic Phenotype.

Selina Hom, Michele Pisano.   

Abstract

Reslizumab (Cinqair), an interleukin-5 antagonist for severe eosinophilic asthma.

Entities:  

Year:  2017        PMID： 28890642      PMCID： PMC5565129     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  2 in total

Review 1.  Inflammatory cells in asthma: mechanisms and implications for therapy.

Authors:  Qutayba Hamid; Meri K Tulic'; Mark C Liu; Redwan Moqbel
Journal:  J Allergy Clin Immunol       Date:  2003-01       Impact factor: 10.793

Review 2.  Diagnosis and management of eosinophilic asthma: a US perspective.

Authors:  Hannah H Walford; Taylor A Doherty
Journal:  J Asthma Allergy       Date:  2014-04-11
  2 in total
  8 in total

1.  Preformulation and Evaluation of Tofacitinib as a Therapeutic Treatment for Asthma.

Authors:  Usir S Younis; Ernest Vallorz; Kenneth J Addison; Julie G Ledford; Paul B Myrdal
Journal:  AAPS PharmSciTech       Date:  2019-04-16       Impact factor: 3.246

Review 2.  Current State and Future of Biologic Therapies in the Treatment of Asthma in Children.

Authors:  Elissa M Abrams; Allan B Becker; Stanley J Szefler
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2018-09-17       Impact factor: 1.349

Review 3.  Type 2 immunity in asthma.

Authors:  Marco Caminati; Duy Le Pham; Diego Bagnasco; Giorgio Walter Canonica
Journal:  World Allergy Organ J       Date:  2018-06-26       Impact factor: 4.084

Review 4.  Dendritic Cell-Mediated Th2 Immunity and Immune Disorders.

Authors:  Sunil Kumar; Yideul Jeong; Muhammad Umer Ashraf; Yong-Soo Bae
Journal:  Int J Mol Sci       Date:  2019-05-01       Impact factor: 5.923

5.  Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis.

Authors:  Ahmed Edris; Silke De Feyter; Tania Maes; Guy Joos; Lies Lahousse
Journal:  Respir Res       Date:  2019-08-08

6.  Changes in Type 2 Biomarkers After Anti-IL5 Treatment in Patients With Severe Eosinophilic Asthma.

Authors:  Jae Hyuk Jang; Seong Dae Woo; Youngsoo Lee; Chang Keun Kim; Yoo Seob Shin; Young Min Ye; Hae Sim Park
Journal:  Allergy Asthma Immunol Res       Date:  2021-03       Impact factor: 5.764

Review 7.  Targeting Aging Pathways in Chronic Obstructive Pulmonary Disease.

Authors:  Molly Easter; Seth Bollenbecker; Jarrod W Barnes; Stefanie Krick
Journal:  Int J Mol Sci       Date:  2020-09-21       Impact factor: 5.923

Review 8.  Treating severe asthma: Targeting the IL-5 pathway.

Authors:  Stefania Principe; Celeste Porsbjerg; Sisse Bolm Ditlev; Ditte Kjaersgaard Klein; Korneliusz Golebski; Nanna Dyhre-Petersen; Yoni E van Dijk; Job J M H van Bragt; Lente L H Dankelman; Sven-Erik Dahlen; Christopher E Brightling; Susanne J H Vijverberg; Anke H Maitland-van der Zee
Journal:  Clin Exp Allergy       Date:  2021-05-21       Impact factor: 5.018
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.